D.E. Shaw & Co
WHWK

D.E. Shaw & Co’s Whitehawk Therapeutics WHWK Stock Holding History

D.E. Shaw & Co’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-17,796
Closed -$26K – 4964
2024
Q2 		$26K Sell
17,796
-23,292
-57% -$43.2K ﹤0.01% 4259
2024
Q1 		$96.1K Buy
41,088
+17,205
+72% +$33.2K ﹤0.01% 4013
2023
Q4 		$48.2K Buy
23,883
+5,433
+29% +$22.8K ﹤0.01% 4023
2023
Q3 		$89.3K Buy
+18,450
New +$107K ﹤0.01% 3868
2022
Q3 		– Sell
-11,395
Closed -$140K – 5592
2022
Q2 		$140K Buy
+11,395
New +$169K ﹤0.01% 4663

Other funds holding WHWK

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AI
Acuitas Investments Seattle, Washington $1.41M AUM 48.57% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co's WHWK Position: Q3 2024 in Review

D.E. Shaw & Co sold out of Whitehawk Therapeutics (WHWK) in Q3 2024, closing a stake of 17,796 shares — an estimated $26K sold.

D.E. Shaw & Co first reported a position in WHWK in Q2 2022 and held it in 5 quarters. The position peaked at $140K in Q2 2022. 52 funds tracked by Wall St. Rank hold WHWK as of Q3 2024.

  • D.E. Shaw & Co reported no remaining Whitehawk Therapeutics position as of Q3 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 17,796 Whitehawk Therapeutics shares in Q3 2024, an estimated $26K.
  • D.E. Shaw & Co first reported a position in Whitehawk Therapeutics in Q2 2022 and held it in 5 quarters.
  • D.E. Shaw & Co's Whitehawk Therapeutics position peaked at $140K in Q2 2022.
  • 52 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q3 2024.

Based on D.E. Shaw & Co's 13F filing for Q3 2024, filed 14 Nov 2024.